According to CRISPR Therapeutics's latest financial reports the company has $1.69 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $1.69 B | -6.7% |
2022-12-31 | $1.81 B | -23.7% |
2021-12-31 | $2.37 B | 40.75% |
2020-12-31 | $1.69 B | 79.1% |
2019-12-31 | $0.94 B | 106.67% |
2018-12-31 | $0.45 B | 90.46% |
2017-12-31 | $0.23 B | -24.01% |
2016-12-31 | $0.31 B | 102.31% |
2015-12-31 | $0.15 B | 16403.81% |
2014-12-31 | $0.94 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | $0.20 B | -87.71% | ๐บ๐ธ USA |